Dominick Angiolillo
CHIEF & DIS PROF
JX-MEDICINE AT JAX
GRANTS
- GRANTGEM Platelet Aspirin Test Cartridge External Precision ProtocolWerfen-Instrumentation5 May 2026 - 4 May 2027
- GRANTGEM Platelet PRUTest Cartridge External Precision ProtocolWerfen-Instrumentation3 Mar 2026 - 2 Mar 2027
- GRANTRandomized study for double-blind, placebo-controlled evaluation of a single intravenous infusion of BI 765845 and partially-blinded evaluation of a single bolus administration of BI 765845 on top of standard of care in patients with acute myocardial infarctionBoehringer Ingelheim Pharm Inc7 Mar 2025 - 8 Mar 2025
- GRANTT-TAS® wS Method ComparisonHikari Dx18 Nov 2024 - 31 Mar 2025
- GRANTPhase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney DiseaseVertex Pharmaceuticals25 Oct 2024 - 24 Oct 2029
- GRANTA Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Adult Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive MedicationsAlnylam Pharmaceuticals19 Sep 2024 - 20 Feb 2025
- GRANTA phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS)Dalcor Pharmaceuticals8 Mar 2024 - 8 Mar 2029
- GRANTRevascularization Choices Among under-Represented Groups Evaluation (The Recharge Trial)Patient-Centered Outcomes Research Institute1 Mar 2024 - 1 Mar 2029
- GRANTA randomized, placebo-controlled, parallel-group, investigator- and participant-blinded Phase 2a study to investigate the efficacy, safety, and tolerability of DFV890 for inflammatory marker reduction in adult participants with coronary heart disease and elevated hsCRPNovartis Pharmaceuticals Corporation27 Oct 2023 - 21 Aug 2025
- GRANTCare4Today StudyJanssen Research and Development27 Sep 2023 - 5 Sep 2024
- GRANTIOCYTE AMI-3: A randomized, double-blind, placebo-controlled, multicenter study of intravenous FDY-5301 in subjects with an anterior ST-elevation myocardial infarctionFaraday Pharmaceuticals2 Aug 2023 - 17 Nov 2025
- GRANTMedtronic Electrophysiology Fellowship Grant 20241 Jul 2023 - 30 Jun 2024
- GRANTOne-month DAPT In CABG PatieNts: the ODIN trialCanadian Institutes of Health Research1 Apr 2023 - 31 Mar 2030People funded by this grant:
- Gaudino M,
- Redfors B,
- Ruel M,
- Sandner S,
- Angiolillo D
- GRANTCanadian Institutes of Health Research1 Apr 2023 - 31 Mar 2030People funded by this grant:
- Wells GA,
- Fremes SE,
- Voisine P,
- Noiseux N,
- Farkouh ME
- GRANTAssessment of Individual Risk of Cardiovascular Events by Platelet FcGammaRIIaProlocor18 Apr 2022 - 13 May 2025
- GRANTA Study of Contrast-induced Acute Kidney Injury Prediction Using the RENISCHEM L-FABP Assay at the Point-of-Care (SAKURA-POC)Hikari Dx15 Nov 2021 - 11 May 2026
- GRANTUFF Scott R. MacKenzie Foundation GrantScott R Mackenzie Foundation1 Jan 2021 - 2 Jan 2021
- GRANTImpact of Timing of Pharmacodynamic Assessments on Measures of Platelet Reactivity in Patients Undergoing Percutaneous Coronary Intervention Treated with CangrelorChiesi USA30 Nov 2020 - 30 Nov 2025
- GRANTComparison of the VerifyNow® Aspirin Test and PRUTest® Platelet Reactivity Tests with Investigational Reagent to Reagents Registered in JapanAccriva Diagnostics20 Oct 2020 - 9 Sep 2022
- GRANTPrecision antiplatelet therapy after percutaneous coronary interventionNational Institute of Health Nhlbi15 Jun 2020 - 30 Jun 2026
- GRANTEvaluating Fitness-for-use of Electronic Health Records in Clinical ResearchUS Food and Drug Administration9 Jun 2020 - 29 Sep 2022
- GRANTUFF Scott R. MacKenzie Foundation GrantScott R Mackenzie Foundation1 Jan 2020 - 31 Dec 2021
- GRANTCangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes RegistryChiesi USA31 Oct 2019 - 15 Sep 2026
- GRANTA Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke.Amgen Inc29 Aug 2019 - 1 Aug 2026
- GRANTEarly Feasibility Study of the Edwards Transcatheter Atrial Shunt SystemEdwards Lifesciences16 Aug 2019 - 15 Sep 2026